Revue des maladies respiratoires最新文献

{"title":"Airway-delivered propionate boost immune tolerance during allergic asthma in mice","authors":"HL. Mai ,&nbsp;B. Misme-Aucouturier ,&nbsp;M. Decarvalho ,&nbsp;J. Marteau ,&nbsp;E. Martin ,&nbsp;E. Nguyen ,&nbsp;S. Brouard ,&nbsp;G. Bouchaud","doi":"10.1016/j.rmr.2025.02.036","DOIUrl":"10.1016/j.rmr.2025.02.036","url":null,"abstract":"<div><h3>Background</h3><div>Allergic Asthma's pathomechanism is essentially a disruption of bronchial homeostasis characterized by an increase in proinflammatory mediators such as T and B effector cells, over immune regulatory cell signaling. Recent work has brought to the forefront the pivotal role of gut microbial metabolites, SCFAs, in abrogating the cardinal features of asthma, such as airway inflammation and AHR, via induction of tolerogenic pathways, tipping the balance towards homeostasis recovery.</div></div><div><h3>Objective</h3><div>The goal was to investigate on a broader scale the immune-regulatory role of propionate in allergic airway- inflammation, in vivo, in an asthma mouse model, and in vitro on human B cell behavior.</div></div><div><h3>Material and Methods</h3><div>The preventive effect of propionate was tested in vivo by treating (or not) BALB/c mice with airway-delivered propionate during house dust mite (HDM) allergen induction of asthma, at the indicated time points. Asthma-related features such as airway function and inflammation were assessed through airway hyperresponsiveness (AHR) measurement, and immune cell profile analysis performed on blood, bronchoalveolar lavage fluid, lungs and spleen, respectively. In vitro, proliferation, survival and intracellular IL-10 expression of isolated purified human B cells was determined upon propionate treatment or not, by flow cytometry.</div></div><div><h3>Results</h3><div>In vivo, Propionate treatment ameliorated AHR after allergic challenge and reduced eosinophil, neutrophil and T lymphocyte but not macrophages extraversion to the lungs. Lung tissue from propionate treated allergic mice showed increased Treg cells, decreased Th2 and Th17 cells and increased B regulatory IL-10 producing cells and Granzyme B cells compared to asthmatic controls. In vitro, propionate dose dependently reversed CPG, CD₄₀L induced B cell proliferation and IL-10 secretion.</div></div><div><h3>Conclusion</h3><div>Direct lung delivery of propionate improved allergen-induced airway inflammation by attenuating lung eosinophilia, neutrophilia and AHR. As well as Treg and B reg over effector cell differentiation in vivo and inhibited B cell Proliferation in vitro. Authors do not have conflict of interest to declare.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Pages 199-200"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting mucus hyperproduction in COPD using siRNA-loaded switchable lipid nanoparticles to silence SPDEF","authors":"TP. Pivetta ,&nbsp;A. Guédin-Beaurepaire ,&nbsp;E. Latouille ,&nbsp;E. Maurat ,&nbsp;M. Thumerel ,&nbsp;P. Berger ,&nbsp;I. Dupin ,&nbsp;J. Leblond Chain","doi":"10.1016/j.rmr.2025.02.039","DOIUrl":"10.1016/j.rmr.2025.02.039","url":null,"abstract":"<div><h3>Introduction</h3><div>Mucus hyperproduction is a key component of chronic obstructive pulmonary disease (COPD), participating to airflow limitation and associated with an increased all-cause mortality. SAM-pointed domain-containing ETS transcription factor (SPDEF) is an intracellular transcription factor required for goblet cell differentiation. Downregulating SPDEF expression using siRNA is a therapeutic option to reduce mucus hyperconcentration and restore mucociliary clearance. However, several biological barriers such as potential immunostimulatory effects, mucus penetration and bronchial epithelial delivery still hamper the efficacy of RNA therapies for lung diseases. Here, using switchable lipid nanoparticles (LNPs) to deliver SPDEF siRNA, we aim at evaluating the potential of targeting SPDEF in relevant human models including an air-liquid interface.</div></div><div><h3>Methods</h3><div>Primary bronchial epithelial cells derived from pulmonary samples were collected after thoracic surgery of COPD and non-COPD patients. Cells were cultivated at the air-liquid interface to obtain a fully differentiated epithelium with a mucus layer. Lipid nanoparticles were prepared by rapid mixing of lipids in ethanol with siRNA targeted against SPEDF in PBS buffer. After the exposure of epithelial cells to siRNA-LNPs during 4<!--> <!-->h, siRNA uptake was evaluated by flow cytometry and confocal imaging. Silencing efficiency was assessed by RT-qPCR and western blot 48 and 72<!--> <!-->h after exposure.</div></div><div><h3>Results</h3><div>The siRNA-LNP were able to efficiently penetrate into differentiated cells in ALI culture. Confocal imaging confirmed that siRNA have crossed the mucus layer and penetrated within the cytoplasm of epithelial cells. SPDEF silencing was achieved 48<!--> <!-->hours after siRNA-LNPs exposure at the RNA level, and at 72<!--> <!-->h at the protein level. The level of silencing was unchanged in cells derived from control subjects compared with those obtained from patients with COPD.</div></div><div><h3>Conclusion</h3><div>LNPs are able to overcome the mucus layer and are internalized into differentiated epithelial cells of a translational patient-derived model. This strategy can be used to deliver SPDEF siRNA, that efficiently downregulate SPDEF expression. These results highlight the potential of this switchable lipid nanoparticle formulation to carry out siRNA drugs for COPD treatment.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 201"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application de la microscopie à force atomique dans l’analyse fonctionnelle des éosinophiles","authors":"V. Spasovski ,&nbsp;A. Ecrement ,&nbsp;T. Gasser ,&nbsp;C. Elie-Caille ,&nbsp;G. Rolin ,&nbsp;C. Barnig","doi":"10.1016/j.rmr.2025.02.041","DOIUrl":"10.1016/j.rmr.2025.02.041","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Les éosinophiles sont des cellules du système immunitaire appartenant à la famille des granulocytes. Ces cellules possèdent de nombreuses fonctions comme l’élimination des pathogènes, tout en jouant un rôle dans l’homéostasie tissulaire et l’immunorégulation. Les éosinophiles peuvent changer de morphologie en réponse à une activation, une adhésion, une migration, ou des interactions cellulaires. La microscopie à force atomique (AFM ou Atomic Force Microscope) a émergé ces dernières années comme un outil précieux pour diverses applications physiques et biologiques. En biologie ultrastructurale, l’AFM permet de détecter des caractéristiques morphologiques sub-nanométriques. Grace à l’AFM, il est ainsi possible d’observer des modifications morphologiques et de mieux comprendre les mécanismes sous-jacents à l’activation et à la fonction des éosinophiles.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Nous avons développé différents modèles fonctionnels des éosinophiles. Tout d’abord, un modèle d’adhésion utilisant de la fibronectine a été étudié en plaçant les éosinophiles dans des puits coatés préalablement avec de la fibronectine (20&lt;!--&gt; &lt;!--&gt;μg/mL pendant 24&lt;!--&gt; &lt;!--&gt;h à 4&lt;!--&gt; &lt;!--&gt;°C). L’adhésion des éosinophiles a été mesurée au cours du temps. Nous avons également mis au point un modèle de libération de pièges extracellulaires par les éosinophiles (EETosis ou eosinophil extracellular trap). L’induction de l’EETosis par le Phorbol myristate acetate (PMA) (50&lt;!--&gt; &lt;!--&gt;ng/mL) a été suivie en temps réel avec un microscope (Incucyte S3, Sartorius) en utilisant un colorant fluorescent vert spécifique aux acides nucléiques. Enfin, l’imagerie par AFM a été réalisée en mode contact (pointe DI 0,3&lt;!--&gt; &lt;!--&gt;N/m, Nanowizard 3, Bruker, USA) sur des cellules Eol-1 différenciées par action d’acide butyrique (0,5&lt;!--&gt; &lt;!--&gt;mM) et après fixation s au glutaraldéhyde (0,5 %) sur des lames en verre.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Nous avons observé une augmentation significative de l’adhésion des éosinophiles en présence de fibronectine, avec un pic à 1 heure (8,1 % &lt;em&gt;vs.&lt;/em&gt; 65,58 %). L’induction de l’EETosis était très nette lorsque les éosinophiles sont activés avec un pic à 10&lt;!--&gt; &lt;!--&gt;heures (1,81 % &lt;em&gt;vs.&lt;/em&gt; 38,2 %). L’imagerie par AFM a révélé des différences morphologiques et physiques notables entre les cellules Eol-1 différenciées et non différenciées, démontrant la faisabilité de cette technique pour observer des changements morphologiques des éosinophiles.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Nos modèles fonctionnels et les techniques d’imagerie par AFM développés dans cette étude ouvrent de nouvelles perspectives pour l’analyse détaillée des propriétés morphologiques et mécaniques des éosinophiles. Cette approche novatrice nous permettra de suivre avec précision les modifications induites par l’activation, l’adhésion et autres stimulations des éosinophiles, améliorant ainsi notre compréhension de leurs fonc","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 202"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Evaluation of compliance with prescription proposals for COPD in the Alsace region of France].","authors":"T Grosz, G Calcaianu, C Palpacuer, M Riou, L Kassegne, C Marcot, T Degot, J Leroux, L Kalmuk, M Fore, R Kessler, B Renaud-Picard","doi":"10.1016/j.rmr.2025.03.002","DOIUrl":"https://doi.org/10.1016/j.rmr.2025.03.002","url":null,"abstract":"<p><strong>Introduction: </strong>The use of inhaled treatments for chronic obstructive pulmonary disease (COPD) in France follows the management proposals issued by the Société de Pneumologie de Langue Française (SPLF). We conducted a retrospective study in two hospitals in Alsace, France to determine the rate of compliance with the recommended treatments.</p><p><strong>Methods: </strong>Data were collected from patients with follow-up for COPD between August 2022 and January 2023. Asthma-COPD Overlap and Overlap syndrome phenotypes were excluded from the study. The data were extracted from the patient's most recent pulmonology consultation at one of the two centers.</p><p><strong>Results: </strong>Out of the 250 patients recruited, 183 (73.2%) had compliant prescriptions. Among those with non-compliant prescriptions, 38 exhibited over-prescribing (56.7%), often secondary to inappropriate use of inhaled corticosteroids (ICS), while 29 cases showed under-prescribing (43.3%), due mainly to lack of treatment with long-acting bronchodilators.</p><p><strong>Conclusions: </strong>Treatment prescription in COPD remains sub-optimal, with a high proportion of therapeutic non-conformities, especially the over-prescribing of ICS. Further studies are needed to develop strategies for improving prescribing practices.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)].","authors":"P Le Guen, N Poté, M-P Debray, V Gounant, B Crestani, C Taillé","doi":"10.1016/j.rmr.2025.03.001","DOIUrl":"https://doi.org/10.1016/j.rmr.2025.03.001","url":null,"abstract":"<p><strong>Introduction: </strong>Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare, chronic condition that predominantly affects women over the age of 60.</p><p><strong>Current knowledge: </strong>DIPNECH combines non-specific clinical signs (chronic cough, dyspnea), bronchial obstruction on PFT and signs suggestive of bronchiolitis on chest CT associated with nodules and multiple micronodules. The diagnosis is most often histological, associating neuroendocrine cell hyperplasia, tumorlets and, inconsistently, carcinoid tumors and constrictive bronchiolitis.</p><p><strong>Prospects: </strong>There are currently no recommendations for DIPNECH treatment and the literature is limited to case reports and retrospective series. Inhibitors of mTOR and somatostatin analogs are possible treatments requiring validation by clinical trials. Functional follow-up and CT scan monitoring are necessary in order to detect complications.</p><p><strong>Conclusions: </strong>DIPNECH is a rare, usually insidious pathology, and may in some cases expose the patient to a risk of tumor and chronic respiratory failure. The diagnosis should be made in the event of a chronic cough in a middle-aged woman.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Hearing loss leading to the diagnosis of granulomatosis with polyangiitis: An unusual case in the Afro-Caribbean population].","authors":"S Neveu, J Antonowicz, M Colantonio, R Deleris, C Raherison-Semjen","doi":"10.1016/j.rmr.2025.02.092","DOIUrl":"https://doi.org/10.1016/j.rmr.2025.02.092","url":null,"abstract":"<p><p>Granulomatosis with polyangiitis (GPA) was diagnosed in a 65-year-old Afro-Caribbean patient presenting initially with hearing loss and a pseudo-tumoral 6cm lung mass. Lung biopsy findings favored the diagnosis of vasculitis. Rapid disease progression was noted with near-complete deafness and lack of speech, severe renal failure necessitating dialysis, and persisting disturbance of consciousness following tonic-clonic seizures due to posterior reversible encephalopathy syndrome (PRES). The patient died one month after admission due to ARDS secondary to ventilator-associated pneumonia. Otological symptoms are frequently the first signs of GPA and should alert the clinician when concomitant with lung nodules, even among Afro-Caribbean patients, in whom GPA is unusual. GPA is a rare disease occurring nearly exclusively in Caucasian populations and is associated with anti-neutrophil cytoplasm antibodies (ANCA) with anti-proteinase 3 (PR3) specificity. Diagnosis is based on clinical, radiological, and biological findings. While pathology from lung localizations is inconsistently specific and rarely made, it can help to establish the diagnosis. This clinical case aptly illustrates the specific clinical presentation of GPA and the potential severity of its multi-organ manifestations.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire","authors":"","doi":"10.1016/S0761-8425(25)00142-1","DOIUrl":"10.1016/S0761-8425(25)00142-1","url":null,"abstract":"","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 3","pages":"Pages iii-iv"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143679970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Actualisation des recommandations de prise en charge des pneumonies aiguës communautaires chez l’adulte par la Société de pathologie infectieuse de langue française (SPILF) et la Société de pneumologie de langue française (SPLF). Avec le soutien de la Société de réanimation de langue française, (SRLF), de la Société française de microbiologie (SFM), de la Société française de radiologie (SFR) et de la Société française de médecine d’urgence (SFMU)","authors":"A. Dinh ,&nbsp;F. Barbier ,&nbsp;J.-P. Bedos ,&nbsp;M. Blot ,&nbsp;V. Cattoir ,&nbsp;Y.-E. Claessens ,&nbsp;X. Duval ,&nbsp;P. Fillâtre ,&nbsp;M. Gautier ,&nbsp;Y. Guegan ,&nbsp;S. Jarraud ,&nbsp;A. Le Monnier ,&nbsp;D. Lebeaux ,&nbsp;P. Loubet ,&nbsp;C. de Margerie ,&nbsp;P. Serayet ,&nbsp;Y. Tandjaoui-Lambotte ,&nbsp;E. Varon ,&nbsp;Y. Welker ,&nbsp;D. Basille","doi":"10.1016/j.rmr.2025.01.003","DOIUrl":"10.1016/j.rmr.2025.01.003","url":null,"abstract":"","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 3","pages":"Pages 168-186"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact de l’activation de Rac1 dans la dégranulation des éosinophiles au cours de l’asthme sévère","authors":"H. Bergereau ,&nbsp;D. Hassoun ,&nbsp;Q. Marquant ,&nbsp;M. Rousselle ,&nbsp;A. Magnan ,&nbsp;G. Loirand ,&nbsp;V. Sauzeau","doi":"10.1016/j.rmr.2025.02.006","DOIUrl":"10.1016/j.rmr.2025.02.006","url":null,"abstract":"<div><div>L’asthme est une pathologie chronique des voies aériennes caractérisée par une inflammation exacerbée et une hyperréactivité associée à un remodelage bronchique. Malgré les biothérapies innovantes, l’asthme sévère reste, dans certains cas, incontrôlé et nécessite de nouvelles approches thérapeutiques. La GTPase Rac1 a été identifiée récemment comme acteur majeur dans l’hyperréactivité et le remodelage bronchique. Dans cette étude, nous mettons en évidence une suractivation de Rac1 dans les éosinophiles pulmonaires de patients asthmatiques. Identifier le rôle de la GTPase Rac1 dans les mécanismes moléculaires du polynucléaire au cours de l’asthme allergique permettrait de valider Rac1 comme cible thérapeutique innovante dans l’asthme sévère.</div></div><div><div>Asthma is a chronic airway disease characterized by exacerbated inflammation, hyperresponsiveness, and associated bronchial remodeling. Despite innovative biotherapies, severe asthma remains largely uncontrolled, highlighting the need for new therapeutic approaches. Rac1 GTPase has recently been identified as a major contributor to bronchial hyperresponsiveness and remodeling. In this study, we demonstrate Rac1 overactivation in pulmonary eosinophils of asthmatic patients. Identifying the role of Rac1 GTPase in the molecular mechanisms of polymorphonuclear cells during allergic asthma could validate Rac1 as an innovative therapeutic target for severe asthma.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 3","pages":"Pages 121-124"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cibler la voie du TGF-β dans la fibrose pulmonaire : une stratégie toujours d’actualité ?","authors":"L. Biziorek ,&nbsp;M. Dériot ,&nbsp;P. Bonniaud ,&nbsp;F. Goirand ,&nbsp;O. Burgy","doi":"10.1016/j.rmr.2025.02.007","DOIUrl":"10.1016/j.rmr.2025.02.007","url":null,"abstract":"<div><div>La fibrose pulmonaire idiopathique (FPI) est une pathologie rare, progressive et fatale et ses traitements pharmacologiques sont peu efficaces. Le TGF-β est une cytokine majeure du processus fibrosant et la signalisation intracellulaire associée à l’activation des récepteurs au TGF-β est complexe. Cette revue résume les stratégies d’inhibition de la voie du TGF-β. Les stratégies et les principales cibles thérapeutiques potentielles décrites durant ces dernières années sont également présentées, en soulignant comment elles pourraient débouchées sur de nouveaux traitements pour la fibrose pulmonaire.</div></div><div><div>Idiopathic pulmonary fibrosis (IPF) is a rare, progressive and fatal disease without pharmacologic curative treatments for the patients. TGF-β is a crucial cytokine in the fibrotic process, and its intracellular signaling pathways are complex and rely on the activation of its receptor. This review summarizes our knowledge on the regulatory checkpoints of the TGF-β signaling. In addition, the main strategies and key potential therapeutic targets identified over recent years are presented, with particular emphasis laid on how they can be used to develop new treatments for pulmonary fibrosis.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 3","pages":"Pages 125-129"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}